Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

Through skiing and snowboarding, a local nonprofit strives to provide a new therapeutic avenue for veterans suffering from the calamities of war.

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...

A University of Michigan AI model diagnoses more than 50 brain disorders from MRI scans in seconds, with up to 97.5 percent accuracy.

At Envision Summit 2026 in Puerto Rico, Inder Paul Singh, MD, discussed office-based surgery and the evolving concept of interventional glaucoma in a CE Spotlight Symposium with Mary Qiu, MD, and ...

For years, rising rates of myopia—or nearsightedness—have been widely attributed to increased screen time, especially among children and young adults. But new research from scientists at the SUNY ...